Document is current
Any future updates will be listed below
-
Authors
He, Wenhua
Chen, Peng
Lei, Yupeng
Xia, Liang
Liu, Pi
Zhu, Yong
Zeng, Hao
Wu, Yao
Ke, Huajing
Huang, Xin
Cai, Wenhao
Sun, Xin
Huang, Wei
Sutton, Robert
Zhu, Yin
Lu, Nonghua https://orcid.org/0000-0003-4373-551X
-
Funding
Funding for this research was provided by:
National Key Clinical Specialty Discipline Construction Program of China ((2011)872)
National Natural Science Foundation of China (81660114, 81860122)
Jiangxi Province Outstanding Youth Talent Funding Program (20192BCBL23021)
Science and Technology Research Project of Jiangxi Provincial Department of Education (60125)
- License Information
-
More Information
Article History
Received: 4 November 2021
Accepted: 30 January 2022
First Online: 3 March 2022
Declarations
:
: This trial was registered (ClinicalTrials.gov, No. NCT02543658) and conducted adhering to a protocol that was approved by the Medical Ethics Research Committee of our hospital (2015, No. 011). Written informed consent was obtained from a relative prior to inclusion.
: Not applicable.
: Robert Sutton has received research support and/or funding from Calcimedica, Cypralis, GlaxoSmithKline, MSD/Merck, and Novartis, has been a consultant for AbbVie, Calcimedica, Cypralis, Eagle Pharmaceuticals, Novartis, and Takeda (all funds to the University of Liverpool), and is collaborating in the IMI2 TransBioLine project with multiple public and private institutions including Janssen, Lilly, MSD/Merck, Novartis, Pfizer, Roche, and Sanofi-Aventis. The other authors declare no conflicts of interest.
